Early immunosuppression therapy improves outcomes in CD8+ T‐cell activated paediatric acute liver failure and hepatitis
Journal of Pediatric Gastroenterology and Nutrition · 2026
DOI: 10.1002/jpn3.70374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Prerna Diksha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Liver Failure, Acute, Immunosuppressive Agents, Immunosuppression Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Objectives
Paediatric acute liver failure (PALF) and hepatitis of indeterminate aetiology with distinctive CD8+ T‐cell rich liver infiltrates is a recently recognised disorder of immune‐mediated dysregulation. We aimed to characterise the clinical phenotype, liver immunohistochemistry, response to immunosuppression (IS) therapy and clinical outcomes up to 24‐months in an Australian cohort.
Methods
Single‐centre retrospective study of patients aged 1–18 years who presented between 2017 and 2022 with hepatitis or acute liver failure with CD8+ rich infiltrates on liver biopsy.
Results
Of the 13 patients identified, 8/13 had CD8+ PALF and 5/13 had CD8+ hepatitis. Median age at presentation was 10.8 years (interquartile range [IQR] 7.8–12.3), and 85% were male. Peripheral lymphopenia was noted in 85% of patients. Corticosteroids (CS) were commenced in 10/13 (77%) patients at a median of 13 days post‐illness‐onset (IQR 9–14). Maintenance IS was initiated in 7/10 (70%) patients, at a median of 20 days post‐illness‐onset (IQR 19–37), with tacrolimus commenced in 4/7 (57%) patients. At 24‐month follow‐up, 100% of patients were alive, 9/13 (69%) survived with native liver (4/8 with PALF; 5/5 with hepatitis), 4/8 (50%) with PALF required liver transplantation and 2/13 (15%) developed aplastic anaemia and recovered without haematopoietic stem cell transplantation. Successful withdrawal of IS was achieved in 50% patients with their native liver.
Conclusions
Evaluation of liver immunohistochemistry and peripheral T‐cell subset analysis is essential for identification of patients with PALF and hepatitis with CD8+ T‐cell predominant liver injury. Early CS and adjunct IS are safe and effective in achieving favourable outcomes at 24 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Melbourne, Victoria, Australia.
- Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
- Department of Paediatrics, University of Melbourne, Victoria, Australia.
- Department of Anatomical Pathology, Royal Children's Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Prerna Diksha
Förderung
- None
Zitieren
APA
Diksha, P., Hardikar, W., Oliver, M., Yap, J., Hywood, J., Alex, G., Ho, S. S. C., McGrath, K., & Bannister, E. (2026). Early immunosuppression therapy improves outcomes in CD8+ T‐cell activated paediatric acute liver failure and hepatitis. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70374
Vancouver
Diksha P, Hardikar W, Oliver M, Yap J, Hywood J, Alex G, et al. Early immunosuppression therapy improves outcomes in CD8+ T‐cell activated paediatric acute liver failure and hepatitis. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70374
BibTeX
@article{Diksha2026,
author = {Diksha, Prerna and Hardikar, Winita and Oliver, Mark and Yap, Jason and Hywood, Jack and Alex, George and Ho, Shaun S C and McGrath, Kathleen and Bannister, Elizabeth},
title = {Early immunosuppression therapy improves outcomes in CD8+ T‐cell activated paediatric acute liver failure and hepatitis},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70374}
}
EUVIMED